Charles & Colvard (CTHR) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
30 Sep, 2025Executive summary
Net sales declined 27% year-over-year to $22.0 million, with losses of $14.4 million and negative cash flow from operations of $7.4 million for the year ended June 30, 2024.
The company faces substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and a $4.8 million settlement related to the Wolfspeed arbitration.
Strategic actions included cost reductions, supply chain consolidation, and a 1-for-10 reverse stock split to regain Nasdaq compliance.
The company continues to focus on e-commerce, product innovation, and expanding its lab-grown diamond and moissanite jewelry offerings.
Financial highlights
Net sales: $21.96 million in FY2024 vs. $29.95 million in FY2023, a 27% decrease.
Net loss: $14.36 million in FY2024 vs. $19.58 million in FY2023.
Gross margin: Product line gross profit was $10.1 million in FY2024, down from $14.8 million in FY2023.
Finished jewelry accounted for 92% of sales; loose jewels 8%.
Cash and cash equivalents at year-end: $4.1 million, with $2.3 million in short-term debt.
Outlook and guidance
Management is focused on stabilizing operations, disciplined spending, and cost management to address liquidity challenges.
The company is evaluating financing options, cost-saving actions, and potential inventory liquidation to fund operations.
Strategic priorities include operational efficiency, product differentiation, and expanding direct-to-consumer channels.
Latest events from Charles & Colvard
- Court-ordered annual meeting set for October 13, 2025, with limited agenda and board elections.CTHR
Proxy Filing1 Dec 2025 - Shareholders face a contested Board election and key governance votes amid ongoing financial challenges.CTHR
Proxy Filing1 Dec 2025 - Director nominations by a shareholder were invalidated; Board to recommend elections at the Annual Meeting.CTHR
Proxy Filing1 Dec 2025 - Proxy contest seeks to replace four directors to address financial and governance concerns.CTHR
Proxy Filing1 Dec 2025 - Shareholders face a contested Board election amid calls for leadership change and strategic overhaul.CTHR
Proxy Filing1 Dec 2025 - Riverstyx seeks board control with three nominees and challenges a dilutive stock issuance.CTHR
Proxy Filing1 Dec 2025 - Board recommends its director slate, annual say-on-pay, and cost-saving measures amid restructuring.CTHR
Proxy Filing1 Dec 2025